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Abstract
Experimental pain trials have been unable to determine whether cannabinoid analgesia is
attributable to intoxication, analgesic expectancies, and/or pharmacological action. One approach
to resolving this issue involves testing the effects of analgesic expectancies and cannabidiol
(CBD), a non-psychoactive cannabinoid, on human pain reactivity using a balanced placebo
design. Despite its frequent use for pain relief, no experimental research has tested the analgesic
effects of CBD in humans. Using a within-subjects 2 x 2 balanced placebo factorial design, we
experimentally tested the effects of CBD and expectancies for receiving CBD on pain reactivity
(i.e., pain threshold, tolerance, intensity, unpleasantness, conditioned pain modulation, offset
analgesia) by manipulating both drug administration (given inactive substance or given CBD)
and instructions (told inactive substance or told CBD) among 15 healthy humans. Participants
completed 4 separate experimental sessions over the course of 4 weeks and were assigned to a
different manipulation condition at each session: told inactive – given inactive (control); told
active – given active (expectancy+drug); told inactive – given active (drug); and told active –
given inactive (expectancy). We did not find significant effects for pain threshold, tolerance, or
intensity. We found significant reductions in pain unpleasantness for the expectancy, drug, and
expectancy+drug conditions when compared to the control condition. We also observed
significant increases in CPM (e.g., greater pain inhibition) in the expectancy and drug conditions.
Lastly, we found a significant main effect of instructions on OA, such that the OA response was
significantly larger (e.g., greater pain inhibition) when participants were told that they received
CBD, regardless of drug content. Overall, our results indicated that separate pain outcomes can
be differentially affected by CBD and/or expectancies for receiving CBD. These findings suggest
that the analgesic profile for CBD is complex and multifaceted.
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1
The Effects of Cannabidiol and Analgesic Expectancies on Experimental Pain Reactivity
Cannabinoids have long been considered effective for reducing pain (Russo, 2008) and
are frequently proposed as treatment options in pain management (Deshpande et al., 2015).
Cannabinoid use has increased substantially, with approximately 22.2 million current users in the
United States alone (Center for Behavioral Health Statistics and Quality, 2016). Chronic pain,
often defined as pain that extends beyond the expected healing period (Turk & Okifuji, 2001),
affects approximately 100 million American adults, and incurs over $600 billion of economic
burden due to healthcare costs and lost productivity (IOM, 2011). The analgesic effects of
cannabinoids are of increasing interest to scientists and clinicians alike, and research on the
analgesic efficacy of cannabinoids has grown exponentially in recent years (Hill et al., 2017;
Mechoulam & Burstein, 1973). Cannabis is an approved pharmacotherapy for chronic pain in all
US states where medical use is permitted (Bestrashniy & Winters, 2015). Pain is the most
common clinical indication for medical cannabis use (Bonn-Miller et al., 2014; Ilgen et al., 2013;
Light et al., 2014), and individuals have reliably endorsed beliefs that cannabis is helpful for
alleviating pain (Sznitman & Bretteville-Jensen, 2015). However, the analgesic properties of
cannabinoids remain poorly understood.
Empirical Evidence Supporting Cannabinoid Analgesia
The cumulative results from clinical studies have yet to provide conclusive evidence
supporting cannabinoid analgesia. Recent systematic reviews have concluded that there is lowstrength evidence that cannabis-based medicines produce small improvements in neuropathic
pain, but insufficient evidence of cannabinoid analgesia for other types of chronic or acute pain
(Aviram & Samuelly-Leichtag, 2017; Butler et al., 2017; Deshpande et al., 2015; Meng et al.,
2017; Nugent et al., 2017; Stevens & Higgins, 2017; Whiting et al., 2015). There is an emerging
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consensus among reviewers that there is no high-quality evidence supporting the effectiveness of
cannabinoids in treating any chronic pain condition (Deshpande & Mailis, 2018; Hauser &
Fitzcharles, 2018; Hauser, Fitzcharles, et al., 2017; Hauser, Petzke, et al., 2017; Nugent et al.,
2017; Stockings et al., 2018). Additionally, numerous confounding factors covary with pain in
clinical populations (e.g., depression) that make it difficult to evaluate analgesia (A. E. Olesen et
al., 2012).
Laboratory pain assessments in healthy participants may be better suited to investigate
the analgesic properties of cannabinoids (Arendt-Nielsen, 1997; Arendt-Nielsen et al., 2007; A.
E. Olesen et al., 2012). Experimental pain paradigms avoid confounds present in clinical data by
studying how controlled cannabinoid doses affect quantifiable responses to painful stimuli
(Cooper et al., 2013). Furthermore, experimental studies are capable of testing the effects of
cannabinoids on different pain outcomes (e.g., intensity, unpleasantness, threshold, tolerance)
that reflect unique dimensions of the pain experience. A recent meta-analytic review of the
experimental literature concluded that cannabinoids may prevent the onset of experimental pain
by producing small increases in pain thresholds, but do not appear to reduce the intensity
(sensory dimension) of experimental pain that is already being experienced (De Vita et al.,
2018). Instead, these substances make experimental pain feel less unpleasant (affective
dimension) and more tolerable, suggesting a notable influence on affective processes (De Vita et
al., 2018). These observations have shed light on the analgesic properties of cannabinoids and
have highlighted the utility of experimental pain methods. What remains unclear, however, is
whether cannabinoid-induced improvements in the affective dimension of pain are influenced by
intoxicating effects and/or analgesic expectancies.
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To date, every experimental pain study of cannabinoid analgesia has administered
psychoactive cannabinoids (e.g., delta-9-THC) that confer psychoactive (e.g., feeling “high”)
effects (De Vita et al., 2018). Despite blinding procedures in crossover trials, many participants
in cannabinoid studies are still able to distinguish between placebo and active conditions due to
the strong psychoactive effects of cannabinoids (Casarett, 2018). In addition to confounding
blinding procedures, these effects may interact with widely held expectancies (e.g., cannabis
reduces pain) among participants to influence pain responding and possibly produce placebo
analgesia. Given these methodological limitations, the small effect sizes in the literature may
very well be driven primarily by analgesic expectancies, rather than drug effects on pain
processing. For this reason, there is a significant need for experimental research designed to test
the influences of non-psychoactive cannabinoids (e.g., cannabidiol) and analgesic expectancies
on pain (De Vita et al., 2018).
The Role of Cognitive Expectancies
Theoretical Considerations
Expectancies are an important cognitive factor that can shape the experience of pain
(Forsberg et al., 2017; Mondloch et al., 2001; Peerdeman, Van Laarhoven, Peters, et al., 2016;
Rasmussen et al., 2009). Many psychological learning theories identify expectancies as
important determinants of behaviors and experiences. The earliest social learning theory posited
that an expected outcome, together with the value a person has placed on that outcome, is a
crucial determinate of behavior (Rotter, 1954). Kirsch (1985; 1997) extended this notion in his
expectancy theory, which posits that expectancies not only influence behavior, but also directly
influence non-volitional responses, such as emotions and sensations (e.g., pain). This concept is
compatible with biopsychosocial theories of pain processing (Pollo et al., 2001; Wall, 1992). For
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example, Neuromatrix Theory posits that psychological processes, such as cognition and
emotion, are primary contributing factors to the pain experience (Melzack, 1999). Social
environments influence these factors, as do any side effects from analgesic medications, which
can influence expectancies. Thus, the role of expectancies in analgesia is an essential
consideration, even in models that place a heavy emphasis on mechanistic understandings.
Although several types of expectancies have been proposed in the theoretical literature
(e.g., self-efficacy expectancies, stimulus expectancies), outcome expectancies are believed to
exert the strongest influence on pain, and are considered a primary mechanism underlying
placebo effects (Benedetti, 2014; Horing et al., 2014; Kirsch, 1997). Outcome expectancies may
be acquired via conditioning, observations, and/or verbal instructions (Kirsch, 1985; Kirsch,
1997). One example of an outcome expectancy is a person’s expectation that they have received
a pain-relieving drug (Peerdeman, Van Laarhoven, Peters, et al., 2016). Modifying expectations
for pain relief can induce placebo effects that alter the intensity and unpleasantness of pain (Atlas
& Wager, 2012; Atlas et al., 2012; Forsberg et al., 2017). One such effect, placebo analgesia, is
an acute reduction in pain upon administering a placebo treatment combined with verbal
information that the treatment relieves pain (Flaten & al'Absi, 2012). This robust effect has been
well documented in both clinical and experimental pain studies (Forsberg et al., 2017). By
manipulating expectancies and substance administration in the same research design,
experimental studies can separate the influence of these factors in analgesic treatments. There
have been no such designs implemented in studies that have tested the analgesic effects of
cannabinoids. Instead, existing studies have almost exclusively attributed analgesic responses to
the pharmacological effects of cannabinoids and their respective mechanisms (Lötsch et al.,
2017).
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Analgesic Expectancies for Cannabinoids
Despite receiving little attention in the cannabinoid-pain literature, outcome expectancies
likely influence cannabinoid analgesia. Pain patients have reliably endorsed the belief that
cannabinoid drugs are effective in relieving pain (Corroon & Phillips, 2018; Sznitman &
Bretteville-Jensen, 2015). These widely held beliefs and attitudes about the efficacy of
cannabinoids for reducing pain may produce expectancies for analgesia (Fitzcharles &
Eisenberg, 2018). In turn, these expectancies may influence how participants rate their pain
following cannabinoid administration. Expectancy effects may even be amplified if participants,
especially experienced users, recognize that they have received an active cannabinoid dose (De
Vita et al., 2018; Gertsch, 2018). As such, participants who hold expectancies about cannabinoid
analgesia may rate their pain as being less unpleasant and more tolerable, especially if they
expect that they have received an analgesic cannabinoid. In evidence-based medicine,
randomized control trials need to demonstrate analgesic efficacy beyond expectancy effects
(Gertsch, 2018). Yet, experiments administering psychoactive cannabinoids remain limited in
their ability to manipulate expectancies (Casarett, 2018). One promising approach to resolving
this issue involves testing the effects of analgesic expectancies and cannabidiol (CBD), a nonpsychoactive cannabinoid, on experimental pain in healthy humans using a balanced placebo
design.
Cannabidiol (CBD)
Cannabidiol (CBD) is a non-psychoactive cannabinoid derived from Cannabis sativa L
and its byproducts, including hemp (Corroon & Phillips, 2018; Pisanti et al., 2017). After
tetrahydrocannabinol (THC), CBD is the second most abundant cannabinoid found in cannabis
(Upton & ElSohly, 2014). According to a comprehensive report published by the World Health
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Organization Expert Committee on Drug Dependence (2018), CBD is well tolerated and has
evinced a good safety profile in humans (Iffland & Grotenhermen, 2017). The same report
concluded that CBD does not exhibit effects that would indicate potential for abuse or
dependence. To date, there is no evidence of any public health-related problems associated with
using pure CBD (World Health Organization Expert Committee on Drug Dependence, 2018).
For these reasons, CBD has increasingly attracted therapeutic interest as a cannabis alternative
that does not make users “high” (Russo, 2017).
In the United States, there has been an unprecedented growth in CBD use in the last
several years. Hemp-derived CBD products are readily available for purchase in the US, and
retail sales are projected to reach an excess of $1 billion in the next 5 years (Corroon & Phillips,
2018). Recently, a cross-sectional study of CBD use patterns in the US found that a majority
(62%) of CBD consumers have reported using it to treat medical conditions. Importantly, pain
was by far the most common medical condition for which CBD was used. Among those using
CBD to treat pain, the majority reported believing that CBD works “very well” to “moderately
well” for relieving their pain (Corroon & Phillips, 2018). Despite its frequent use as an analgesic
treatment, no experimental research has tested the analgesic effects of pure CBD on experimental
pain in humans. Given its purported therapeutic effects, as well as widely held beliefs that CBD
is an effective pain reliever, CBD is an ideal candidate for experimental pain trials. As an
additional methodological benefit, expectancy manipulations (e.g., giving participants placebo,
but telling them it is CBD) in CBD trials have a greater chance of succeeding, given the lack of
psychoactive effects from CBD.
The Utility of Quantitative Sensory Testing (QST) in Analgesic Assessment
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Quantitative sensory testing (QST) is the systematic application of quantifiable sensory
stimuli to evaluate perceptual pain reactivity (Boivie, 2003; Cruz-Almeida & Fillingim, 2014;
Hansson et al., 2007; S. S. Olesen et al., 2012). Static QST measures evaluate overall sensitivity
to painful stimulation at a specific moment in time (Arendt-Nielsen & Yarnitsky, 2009; Mogil &
Bailey, 2010; Tesarz et al., 2012; Walk et al., 2009), and include rating the intensity (sensory
dimension), unpleasantness (affective dimension), threshold (level at which painful stimuli are
first perceived), and tolerance (level at which one can no longer withstand a painful stimulus) of
experimental pain (Arendt-Nielsen & Yarnitsky, 2009; Coghill et al., 1999; Schaible, 2006;
Walk et al., 2009). These measures reflect important dimensions of the pain experience that may
be differentially affected by analgesic cannabinoid treatments (De Vita et al., 2018). Although
static measures offer an array of useful information about one’s pain experience, dynamic QST
measures can yield sophisticated insights about the neurobiological mechanisms underlying
analgesia (Arendt-Nielsen et al., 2007).
Placebo analgesia is a psychophysiological phenomenon that is partially mediated by
neurobiological mechanisms (Medoff & Colloca, 2015). Neuroimaging studies have shown that
expectancy-induced placebo analgesia reduces nociceptive processing in the dorsal spinal cord,
implicating top-down inhibiting mechanisms (Eippert et al., 2009). Such findings suggest that
connections between cortical regions and descending pain inhibitory systems are involved in
placebo analgesia (Medoff & Colloca, 2015). Dynamic measures of experimental pain reactivity,
such as conditioned pain modulation (CPM) and offset analgesia (OA) may provide advanced
assessments of the central inhibitory mechanisms underlying analgesic responses (see Appendix
A). These measures assess complex central nervous system mechanisms that modulate pain
perception (Arendt-Nielsen & Yarnitsky, 2009; Cruz-Almeida & Fillingim, 2014; Goodin et al.,
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2013). Conditioned pain modulation (CPM) represents a “pain-inhibits-pain” paradigm, where
participants perceive a painful stimulus as decreasing in intensity when a competing, yet
simultaneous stimulus is applied elsewhere on the body (Granovsky et al., 2015). This reflects an
endogenous spatial pain processing mechanism that involves spinal-medullary-spinal loops (Pud
et al., 2009) and complex interconnectivity of the brainstem (i.e., rostral ventromedial medulla,
periaqueductal gray) with the somatosensory (Piché et al., 2009), prefrontal (Moont et al., 2011;
Song et al., 2006; Wilder-Smith et al., 2004; Youssef et al., 2016), insular (Bogdanov et al.,
2015) and anterior cingulate cortices (Sprenger et al., 2011; Youssef et al., 2016). Offset
analgesia (OA) represents an endogenous temporal pain processing mechanism, where a minimal
(e.g., 1℃) decrease in the intensity of a painful stimulus produces a robust, yet disproportionate
analgesic effect on pain perception (Grill & Coghill, 2002), reflecting nociceptive processing in
the periaqueductal grey, medulla, and locus coeruleus (Derbyshire & Osborn, 2009; Yelle et al.,
2009). Together, these central pain inhibition systems modulate the pain experience (Granovsky
& Yarnitsky, 2013). These measures have the potential to enhance our understanding of the
psychophysiological mechanisms underlying both expectancy and drug effects in cannabinoid
analgesia.
The Current Study
The overall goal of this study was to use the balanced placebo design (see Figure 1) to
test the independent and combined effects of CBD administration and expectancies for receiving
CBD on experimental pain reactivity (i.e., pain intensity, pain unpleasantness, threshold,
tolerance, conditioned pain modulation, offset analgesia) in a sample of healthy pain-free adults.
The study had three main aims.
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Aim 1. To test the effects of an instructional set manipulation (told inactive coconut oil
versus told active CBD) on experimental pain reactivity outcomes among healthy pain-free
adults. We hypothesized a significant main effect of instructions, i.e., that telling participants
they received analgesically active CBD (versus inactive coconut oil) would produce significant
analgesic effects on experimental pain intensity, unpleasantness, threshold, tolerance,
conditioned pain modulation, and offset analgesia, independent of the substance that participants
actually received.
Aim 2. To test the effects of drug administration (given inactive coconut oil versus given
active CBD) on experimental pain reactivity outcomes among healthy pain-free adults. We
hypothesized that there would not be any effects of substance actually administered to the
participant (inactive coconut oil or active CBD) independent of instructions. Therefore we
hypothesized no main effect of substance actually administered on experimental pain intensity,
unpleasantness, threshold, tolerance, conditioned pain modulation, and offset analgesia.
We hypothesized null drug administration effects for several reasons. First, expectancyinduced analgesic effects reported in the experimental literature are large (Forsberg et al., 2017),
while cannabinoid administration effects have been small (De Vita et al., 2018). Thus, CBD
administration effects may be smaller and require more precision to detect, even in studies that
are powered to detect expectancy effects. That is, the projected sample size of a study powered to
detect large-sized expectancy effects may be smaller than one powered to detect small-sized drug
effects. In that event, drug effects, if present, would be less likely to be detected. Second, CBD
consumers often use doses (e.g., 50 mg) that are much smaller than those examined in clinical
trials, which have ranged between 100 mg - 6000 mg (Hurd, 2020). Most people who use CBD
may be using doses that fall well below what has been indicated as clinically effective. We were
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interested in testing a CBD dose (i.e., 50 mg) that was generalizable, but recognized that there is
little empirical evidence supporting the clinical efficacy of CBD in smaller doses. For these
reasons, we hypothesized that we would not find administration effects in our study.
Aim 3. To test the interaction between instructional set and drug administration on
experimental pain reactivity outcomes among healthy pain-free adults. We hypothesized that
there would be no interaction effects on experimental pain intensity, unpleasantness, threshold,
tolerance, conditioned pain modulation, and offset analgesia.
Method
Participants
Individuals from the community were recruited via paper flyers to participate in a foursession experimental study examining the effects of Cannabidiol (CBD) on sensation.
Respondents were screened (see Appendix B) by phone for the following inclusion criteria: (a)
between 18-30 years of age and (b) ability to speak and read English. Respondents were
excluded if they endorsed: (a) any current pain that was either chronic (i.e., lasting longer than 3
months) or acute (i.e., resulting from a recent injury or pain that is not fleeting); (b) current use
of any pain medications; (c) any current or previous diagnosis of chronic medical or psychiatric
conditions; (d) a history or diagnosis of any substance use disorder, or a score of 8 or more on
either the AUDIT or CUDIT-R; (e) current use of any prescription medication for any physical
or mental health condition (except oral contraceptive pills); (f) Current or former
tobacco/nicotine use; (g) coconut allergies (contraindicated for CBD isolate oil solution), and (h)
being pregnant, breast feeding, or planning to become pregnant in the next 4-6 months; (i)
negative expectancies for cannabinoid analgesia (indicating ‘no’ for CBM-Q item 3). Eligibility
criteria were verified in-person at session 1.
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Power Analysis
Given that we predicted significant effects of the instructional set manipulation, but null
effects for drug administration and interactions, power analyses were calculated to estimate the
sample size required to detect effects in the primary (within-subjects) outcomes hypothesized in
Aim 1. To determine the target sample size, we examined effect sizes reported in the literature
from studies that tested the effect of expectancy manipulations on experimental pain outcomes in
healthy humans. In a recent meta-analysis of 58 studies (3557 healthy adults), Forsberg and
colleagues (2017) found that expectancy manipulations (i.e., describing placebo treatment as a
painkiller) produced large (Hedges’ g = 1.24; f = .62) analgesic effects on experimentallyinduced pain in healthy adults. Whereas this meta-analytic review estimated cumulative effect
sizes using Hedges’ g, our a priori power analyses in G*Power3 required imputing effect sizes
using Cohen’s f. Thus, Cohen’s f conversions were used exclusively to conduct power analyses
and we provided both coefficients in the description below for transparency and to assist
replication efforts. Hedges’ g is often used in meta-analyses because it can account for small
sample size bias, and its interpretation is similar to that of Cohen’s d (i.e., the coefficient often
provided in individual studies), with .20, .50, and .80 corresponding to small, medium, and large
effects, respectively (Cohen, 1988). Considering these data and the tests proposed herein, we
selected a more conservative medium-sized estimate (Hedges’ g = .50; f = .25) for our power
analyses. Thus, for Aim 1, a sample of 15 was estimated to afford a power of .82 to detect
medium-sized main effects using a repeated measures ANOVA with 4 within-subjects
conditions.
Procedure
Design overview
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Figure 1 provides an overview of the experimental design. Our study employed a withinsubjects, balanced placebo 2 (instruction) x 2 (administration) factorial design. The balanced
placebo design is an optimal method for dissociating pharmacological effects from cognitive
expectations of receiving a drug (i.e., outcome expectancies; Rohsenow & Marlatt, 1981; Ross et
al., 1962). This design crosses the substance actually administered (given inactive substance vs.
given active substance) with instructions about what substance was administered (told inactive
substance vs. told active substance), and has demonstrated feasibility in research with cannabis
and outcome expectancies (Gunn et al., 2017; Metrik et al., 2012; Metrik et al., 2009).
Participants completed four separate experimental sessions over the course of four weeks and
were assigned to a different manipulation condition at each session: (a) told inactive – given
inactive; (b) told active – given active; (c) told inactive – given active; and (d) told active – given
inactive. The four manipulation conditions were counterbalanced in a pre-determined
randomized order (see Appendix C). A minimum washout period of one week between sessions
was used to prevent carryover effects. Recruitment and enrollment continued until 15
participants completed the entire study (i.e., all four sessions). Our study was pre-registered on
the Open Science Framework (doi: 10.17605/OSF.IO/5UN2D).
Design Considerations. Our decision to use a within-subjects design was informed by
several considerations. Compared to between-subjects approaches, within-subjects designs are
better powered to detect effects with fewer participants. Specifically, small scale studies with
between-subjects designs produce large standard errors, whereas within-subjects designs increase
statistical power, reduce the required sample size, and maximize control of threats to internal
validity, such as extraneous participant variables (Metrik et al., 2009; Stevens, 2002).
Importantly, pain processing and analgesic drug effects can vary greatly between participants
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due to individual differences (Arendt-Nielsen et al., 2007). For these reasons, most experimental
cannabinoid analgesia studies have employed within-subjects designs (De Vita et al., 2018). The
use of within-subjects designs has also been encouraged in cannabinoid trials that employ
balanced placebo designs because of the aforementioned benefits (Metrik et al., 2009).
Despite these strengths, within-subjects designs have limitations worth considering.
Participants who undergo testing in multiple experimental conditions may exhibit carryover
effects from previous sessions (Howell, 2012). The effects of drug administration may “carry
over” into a subsequent session if said effects have not worn off in time. In this regard, most
experimental cannabinoid analgesia trials have employed a washout period, with an average of 7
days being reported in the literature (De Vita et al., 2018). For the current study, a minimum 7day washout period is likely adequate, especially given that CBD effects are far more mild
compared to those of psychoactive cannabinoids (e.g., THC; World Health Organization Expert
Committee on Drug Dependence, 2018). Order effects are another type of carryover effect that,
if not controlled for, can introduce bias into within-subjects studies (Charness et al., 2012;
Greenwald, 1976). To prevent order effects, the order of the experimental conditions can be
counterbalanced across participants, and assignment to each order can be randomized (Field,
2013; Salkind, 2010). This minimizes the risk that condition order will systematically influence
differences between outcomes in each condition. Participant attrition may also be a concern in
within-subjects designs that require multiple sessions. To mitigate this concern, we compensated
participants with a $20 completion bonus in addition to the payments they received for each
session.
Experimental sessions
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Figure 2 provides an overview of the experimental procedure. Respondents who screened
eligible were scheduled for experimental sessions. Participants were asked to refrain from all
non-prescription medications or other substances for the 24 hours preceding their appointments.
Research staff verified abstinence via self-report and BAC bioverification during the first
session. Pregnancy tests were administered to female participants at each session. Two research
assistants, a QST assessor and a dose administrator, conducted sessions. The QST assessor was
blinded to the experimental manipulations (i.e., instructions and administrations). At the first
experimental session, participants provided informed consent and completed baseline self-report
measures before undergoing a pre-manipulation QST assessment. Participants then received the
instructional set (told coconut oil vs. told CBD) and drug administration (given coconut oil vs.
given CBD) combination that corresponded to the counterbalanced order they had been
randomly assigned to. Specifically, the dose administrator told the participant what substance
they were going to receive (instruction set manipulation), and provided either a coconut oil or
CBD oil dose for sublingual administration. Afterwards, participants underwent a 30-minute
absorption period. This timeframe was informed by several factors. First, human cannabinoid
pharmacokinetic research has shown that CBD analytes are detectible in plasma 30 minutes after
sublingual dosing (Huestis, 2007). Second, instructional set manipulations have induced
expectancy effects for cannabis 30 minutes after administering placebo in previous experiments
(e.g., Loflin et al., 2017). Third, this timeframe is consistent with widely-available guidelines for
sublingual CBD use, created by manufacturers of CBD (for examples, see Appendix N).
Following the 30-minute absorption period, participants completed a post-manipulation QST
assessment. Afterwards, participants rated common cannabis-related side effects (i.e. drowsiness,
euphoria, sedation, nausea, dry mouth, and vertigo) using visual analog scales (see Appendix G),
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and indicated whether they believed they received the active CBD dose or inactive substance
(i.e., manipulation check; see Appendix L). Each of the following laboratory sessions followed
the same experimental structure. Experimental sessions lasted approximately 1.5 hours.
Participants received $20 per session as compensation and a $20 completion bonus for finishing
the study (i.e., up to $100 for the entire study). At the end of the experiment, participants were
asked whether they felt deceived about anything during the experiment. If participants indicated
that they felt deceived, they were asked to explain using an open-ended response format (see
Appendix L). This approach to evaluating the credibility of the instructional set manipulation
was chosen given its successful implementation in previous cannabinoid administration research
that has employed the balanced placebo design (Gunn et al., 2017; Metrik et al., 2012; Metrik et
al., 2009). These items were administered via an online survey platform (Qualtrics), and the
researchers left the room to prevent demand effects that may occur in other formats (e.g., a postexperimental interview). At the end of the experiment (i.e., after their fourth session),
participants were fully debriefed and provided with the final compensation.
QST Pain Reactivity Assessment
Experimental pain reactivity outcomes were assessed using contact-heat via the Q-Sense
CPM unit manufactured by Medoc LTD. (Ramat Yishai, Israel). This device utilizes two 30 x 30
mm Peltier-based computerized thermodes, and the accompanying software can employ highly
standardized quantitative sensory testing protocols. Contact heat delivered via thermode has been
used extensively to study mechanisms of pain responding among persons with and without
clinical pain disorders. The Medoc Q-Sense unit has a temperature range of 20°-52°C (with a
heating rate of 2°C/sec and a cooling rate of 1°C/sec), that allows for assessment of dynamic
pain processes (e.g., CPM). Pain ratings are continuously assessed using a computerized visual
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analog scale (CoVAS), manufactured by Medoc LTD. (Ramat Yishai, Israel). The CoVAS unit
has a slider that moves horizontally to placements that correspond with ratings along a visual
analog scale that ranges from 0 (no pain) to 100 (pain as intense as possible). The Medoc
software records a pain rating corresponding to the location of the slider every millisecond,
which enables time series ratings. QST measurements were taken in a small, temperature
controlled room with minimal distractions. The QST assessor initiated the task outside of the
room to further limit distractions and demand effects.
Instructional Set and Drug Administration Manipulations
Instructional Sets. Consistent with previous research examining the effects of
expectancies on experimental pain (Atlas et al., 2012), verbal instructional sets were used to
manipulate the participant’s expectancies for receiving an analgesic substance (CBD) or an
inactive substance (coconut oil). In the control (told coconut oil – given coconut oil) and drug
(told coconut oil – given CBD) conditions, participants were told, “In today’s session, you will
not be receiving the pain-reliever, cannabidiol. Instead, you will be given control dose of coconut
oil, which does not have any effects on anything, including pain.” In the expectancy (told CBD –
given coconut oil) and expectancy + drug (told CBD – given CBD) conditions, participants were
told, “In today’s session, you will be receiving a concentrated dose of cannabidiol, or CBD. This
experimental CBD produces strong pain-relieving effects without making you high, or producing
any other negative mind altering effects.” Information that emphasized the strength of pain relief
was provided to enhance expected analgesic effects of CBD. Instructions were given in such a
way that participants never received the same instruction twice in a row. Instructions for each
condition session were pre-prepared by the principal student investigator (M.D.) and sealed into
envelopes prior to study enrollment. A dose administrator opened the envelope immediately
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before instructions were given to each participant. The blinded QST assessor waited in a separate
office while the dose administrator provided the instructions and dose. The participant was
instructed not to disclose which dose instructions they had received to the QST assessor to
maintain blinding.
Drugs. In conditions where the active drug was received, participants received 50mg of a
CBD isolate (i.e., pure cannabidiol) oil solution manufactured by Infinite CBD, LLP (Colorado,
USA). The product, a CBD Isolate Dropper (see Appendix M), comes in the form of a 30mL
bottle containing 5,000mg of CBD isolate (approximately 8.5mg of CBD per drop). Isolate CBD
crystals are oil-soluble, and this product uses fractionated coconut oil as a base. No other
compounds or flavors are added by the manufacturer, and cannabinoid content and purity are
verified by an independent accredited testing facility (ProVerde Laboratories, Inc.; see Appendix
M) by use of convergence chromatography. In the inactive conditions, participants received a
fractionated coconut oil supplement only. Artificial flavors were used to enhance the
experimental manipulations (see Appendix C). In conditions where participants were told they
were receiving coconut oil, coconut flavoring was added to the substances administered. An inert
‘Mary Jane’ flavor (Perfumer’s Apprentice, LLC, California, USA) was added to substances
administered in conditions where participants were told they were receiving CBD. Dosages for
each condition were pre-prepared by the principal student investigator (M.D.) and placed into
jars labeled with letters (A, B, C, D). Letters corresponding to each condition were included in
the pre-prepared envelopes opened by dose administrators. Dose administrators selected
substances using these letter labels and were thus blinded to the actual content of the jars (see
Appendix C). Both the active and inactive doses were administered sublingually, followed by an
absorption period of 30 minutes. Recent research has reported that CBD is most commonly self-
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administered sublingually as an oil (Corroon & Phillips, 2018). Thus, this method was chosen to
enhance external validity.
Measures
Bioverification Measures
Pregnancy Test. All female participants were required to screen negative for pregnancy
at each session. BFP Pregnancy test strips (99% accuracy rating) were administered to women at
the beginning of each session to screen for current pregnancy.
Alcohol Breathalyzer. All participants were verified as being sober from alcohol prior to
each session (i.e., BAC = 0.00). BAC was assessed via breath analysis (Alco-Sensor FST).
Self-report Assessment Measures
Hazardous Alcohol Use. The Alcohol Use Disorder Identification Test (AUDIT; Babor
et al., 2001; Saunders et al., 1993) is a ten-item instrument that assesses current risk for alcohol
use disorder (see Appendix D). The AUDIT has been shown to be a reliable and valid measure to
identify possible hazardous or harmful alcohol consumption in adults (Reinert & Allen, 2002).
Items on this measure are summed to produce an overall score, with a total of 8 or more
suggesting hazardous use and risk for alcohol use disorder.
Hazardous Cannabis Use. The Cannabis Use Disorder Identification Test - Revised
(CUDIT-R; Adamson et al., 2010) is an eight-item measure (see Appendix E) that has
demonstrated high internal consistency and discriminant validity. Items assess the frequency of
cannabis use behaviors and consequences on a 0 to 4 scale. Items are summed to produce an
overall score, with a cutoff score of 8 or more suggesting hazardous use and risk for cannabis use
disorder. The CUDIT-R has demonstrated high test-retest reliability (r = .87) and high internal
consistency (α = .91) in previous research (Adamson et al., 2010).
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Cannabis-Based Medicine Questionnaire. We developed a brief 10-item questionnaire
to screen out negative expectancies for cannabinoid analgesia (see Appendix F). Participants
were asked to indicate whether cannabis-based medicines were helpful for treating 10 different
clinical conditions, including pain. Respondents who selected ‘No’ for pain were excluded
during recruitment.
Demographic Questionnaire. Participants were asked to report demographic
information, including age, gender, race, ethnicity, education, employment status, annual
income, and, for women, phase of menstrual cycle (see Appendix G).
Past 30-Day Substance Use. The Timeline Followback procedure (TLFB; Babor et al.,
1990; Dennis et al., 2004; Sobell & Sobell, 1992) was used to establish a 30-day retrospective
substance use baseline (see Appendix H). Participants were asked to document the type and
amount of each substance they had used in the previous 4 weeks, including cannabinoid drugs
(including cannabis and CBD), and alcohol. Percentage of days used for each drug was
determined using TLFB data. A 7-day TLFB was given at each follow-up session. The TLFB has
demonstrated excellent test-retest reliability for several substances, including cannabis (ICCs
ranging from .78 - .96; Robinson et al., 2014). The TLFB provides estimates of substance use
with a high degree of accuracy, and has exhibited a high level of agreement (87% agreement for
cannabis) with biological measures (Hjorthoj et al., 2012).
Cannabinoid Use History. The Marijuana History and Smoking Questionnaire (MHSQ;
Bonn-Miller & Zvolensky, 2009) is a 21-item instrument that includes questions about cannabis
use history (e.g., frequency, quantity, age of first use; see Appendix I). Participants were also
asked open-ended questions about whether they had ever used CBD and whether they personally
know anyone who has used CBD.
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Perceived Drug Side-Effects. Consistent with previous research testing the effects of
cannabinoids on experimental pain reactivity (Kraft et al., 2008), common cannabis-related side
effects of drowsiness, euphoria, sedation, nausea, dry mouth, and vertigo were assessed using
visual analog scales (VAS; see Appendix J). Participants were asked to rate the intensity of these
symptoms on a VAS ranging from 0 (not at all) to 100 (extremely intense). Side effects were
measured before and after the experimental manipulation.
Expectancies for Cannabinoid Analgesia. A 20-item questionnaire was developed to
assess participants’ expectancies for cannabinoid analgesia (see Appendix K). Participants were
asked to read statements about cannabis and pain (e.g., cannabis reduces the intensity of pain)
and then rate the extent to which they expect these statements to be true on a 5-point Likert scale
ranging from 0 (definitely not) to 4 (definitely).
Manipulation Checks. A single item was used at the end of each session to assess
whether participants believed they had received the active (CBD) or inactive (coconut oil)
substance. At the end of the experiment, participants were asked whether they felt deceived
about anything during the experiment using an open-ended response format. This approach to
evaluating the credibility of the instructional set manipulation was chosen given its successful
implementation in previous cannabinoid administration research that has employed the balanced
placebo design (Gunn et al., 2017; Metrik et al., 2012; Metrik et al., 2009). These items were
administered via an online survey platform (Qualtrics; see Appendix L), and the researchers left
the room to prevent demand effects that may occur in other formats (e.g., a post-experimental
interview).
Experimental Pain Reactivity Outcomes
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Pain Threshold and Tolerance. A “method-of-limits” protocol was used to assess both
pain threshold and tolerance with a thermode attached to the volar surface of the non-dominant
forearm (McMahon et al., 2013). Specifically, 6 trials of pain stimulation were administered at
30-second intervals with each stimulus increasing in temperature from baseline (32°C) at a rate
of 0.3°C per second. For the first 3 trials, the participant indicated when they first perceived the
stimuli as painful (threshold) using a response device, at which point the temperature was
digitally recorded and returned to baseline. During the last 3 trials, participants used the response
device to indicate when they could no longer withstand the stimulus (tolerance), at which point
the temperature was digitally recorded and returned to baseline. The temperatures recorded
during the first and last 3 trials were averaged to generate mean threshold and tolerance values,
respectively. To determine individualized destination temperatures for each participant during
dynamic pain measurements, we calculated a suprathreshold value as the mid-point (mean)
temperature between threshold and tolerance. This ensures that stimulation is perceived as
painful, yet tolerable, and prevents floor/ceiling effects. In previous work in our lab, pain
threshold (ICC = 0.80), tolerance (ICC = 0.81), and suprathreshold (ICC = 0.83) have
demonstrated excellent test-retest reliability when obtained using these same methods (De Vita et
al., under review).
Pain Intensity and Unpleasantness. Pain intensity and unpleasantness were assessed
using a visual analogue scale (VAS) ranging from 0 (not at all intense/unpleasant) to 100
(maximum intensity/unpleasantness possible). The VAS has shown strong test-retest reliability
and internal consistency in previous research (Price et al., 1994). Participants were asked to
provide ratings at 30-second intervals throughout the continuous application of suprathreshold
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heat pain for 2 minutes. Mean pain intensity and unpleasantness values were obtained by
averaging the ratings across measurement intervals.
Dynamic Pain Measures.
Conditioned Pain Modulation (CPM). CPM was measured using a ‘single test-stimulus’
procedure (see Appendix A) with 2 thermodes to induce concurrent contact heat pain. This
protocol has demonstrated good test-retest reliability and consists of one brief trial (Granovsky et
al., 2015). A ‘test-stimulus’ thermode was attached to the volar surface of the non-dominant
forearm, whereas a ‘conditioning-stimulus’ thermode was placed on the upper posterior of the
opposite arm. During the procedure, the test-stimulus temperature increased from 32°C at a rate
of 2°C per second until it reached the participant’s suprathreshold level. Ten seconds later, the
conditioning-stimulus temperature began increasing at the same rate until it reached the
suprathreshold level. For the following 20 seconds, both thermodes remained at suprathreshold
temperature before returning to baseline. Participants were instructed to continuously rate the
pain intensity of the test-stimulus using the CoVAS.
Offset Analgesia (OA). OA was assessed with a 3-temperature paradigm (see Appendix
A) that utilizes a single thermode attached to the volar surface of the participant’s non-dominant
forearm (Grill & Coghill, 2002). The temperature increased from a baseline level of 32°C at a
rate of 2°C/s until it reached the participant’s predetermined suprathreshold value. Consistent
with published methods (Grill & Coghill, 2002), this temperature was held constant for 5
seconds, followed by a 1°C increase for an additional 5 seconds, and then a subsequent 1°C
decrease for 20 seconds, before returning to baseline. Participants were instructed to rate their
pain intensity continuously using the CoVAS.
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Dynamic QST Scores. For both CPM and OA, the magnitude of response (i.e., pain
inhibition) was calculated from CoVAS data using the ‘percent decrease’ formula (Marieke
Niesters et al., 2011):

–

× 100. This quantifies the individualized change

between peak (i.e., highest) and nadir (i.e., lowest) values within each participant’s CoVAS timeseries (M. Niesters et al., 2011; Marieke Niesters et al., 2011). These methods for measuring
CPM (ICC = 0.66) and OA (ICC = 0.69) have demonstrated test-retest reliability in the good to
excellent range in previous work in our lab (De Vita et al., under review).
Data Analytic Strategy
All statistical analyses were conducted using SPSS, version 23 (IBM, Armonk, New
York). Descriptive statistics pertaining to sociodemographics and substance use were calculated
and presented as a summary of the sample characteristics. Pre-post change scores were computed
for each experimental pain outcome. A series of bivariate correlations tested zero-order
associations between age, gender, CBD ever use, cannabis ever use, expectancies for
cannabinoid analgesia, and order assignment with pain threshold, pain tolerance, pain intensity,
pain unpleasantness, conditioned pain modulation, offset analgesia change scores in each
manipulation condition. To evaluate the credibility of the instructional set manipulation, we
determined the proportion of participants who report receiving the drug described in their
instructional set for each condition (Gunn et al., 2017; Metrik et al., 2012; Metrik et al., 2009).
We also examined open-ended responses to characterize participants who suspected deception.
Consistent with the balanced placebo design, the data analytic strategy employed twoway repeated measures ANOVAs to test for main and interaction effects on QST outcomes and
side-effects. Partial eta squared (η2p) was used to characterize effect size for ANOVA results,
with .01, .06, and .14 corresponding to small, medium, and large effects, respectively (Cohen,
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1988). Significant interactions were followed up with paired samples t-tests to identify simple
main effects between conditions. Cohen’s d was used to characterize effect sizes for simple main
effects, with .20, .50, and .80 corresponding to small, medium, and large effects, respectively
(Cohen, 1988). All significance testing was conducted with an alpha level set at .05.

Results
Participant Characteristics
Participant flow is illustrated in the CONSORT diagram in Figure 3. Research staff
telephone screened 75 respondents and 25 were deemed eligible. Throughout the study, 21
eligible respondents were scheduled for a baseline session. Of these, 5 were no-shows for their
first appointment and 4 were waitlisted. Sixteen eligible participants were enrolled in the study
and randomized. Incomplete data from 1 participant who did not return after the first session
were excluded from analyses. A total of 15 participants completed all four study sessions and
were included in analyses.
Participant characteristics (e.g., demographics, substance use variables) are reported in
Table 1. The sample was predominately comprised of young adults (67% Female; Mage = 20.73,
SD = 2.60). Approximately 67% of participants endorsed having ever used CBD, whereas 80%
reported personally knowing someone who has used CBD. Thirteen (86.7%) participants
endorsed current or ever use of cannabis and an average of 3.10 years of cannabis use. At session
1, participants reported using alcohol and cannabinoid drugs for 17.33% and 10.22% of days in
the past 30 days.
Bivariate Correlations
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Bivariate analyses are provided in Table 2. Counterbalanced order assignment was not
significantly correlated with any of the QST outcomes in any condition (all ps > .05). Pain
intensity change scores in the control condition were negatively correlated with age (r = -.59, p <
.05). Whereas pain unpleasantness change scores in the drug condition were positively correlated
with gender (i.e., more change in males; r = .54, p < .05), these scores were negatively correlated
with cannabis ever use (r = -.56, p < .05). Expectancies for cannabinoid analgesia were
positively correlated with changes in pain tolerance in the expectancy condition (r = .56, p <
.05), but negatively associated with changes in CPM in the expectancy condition (r = -.70, p <
.01). None of the between-subjects factors were correlated with QST outcomes in all four
experimental conditions.
Manipulation Checks
After each session, all participants reported receiving the substance described in their
instructional set for each condition. Three participants endorsed general suspicions about being
deceived during the experiment. In their open ended responses, two of these participants
described suspicions about psychology studies in general and suspected that the study goals may
different than what had been initially described. One participant reported feeling generally
suspicious about being told not to reveal their instruction set to the QST assessor to maintain
blinding. None of these participants endorsed feeling deceived about drug content.
Side Effects
Table 3 presents results from the two-way repeated measures ANOVAs testing the effects
of instruction and administration on side-effects typically associated with cannabis use. There
were no main or interaction effects for any of the side-effects measured (all ps > .05).
Experimental Pain Reactivity Outcomes
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Table 4 presents results for the two-way repeated measures ANOVAs for QST outcomes.
Means and standard deviations for QST outcomes in each condition are provided in Table 5.
Figure 4 presents the mean change scores in each condition for all static QST outcomes.
Threshold
As seen in Table 4, results from the two-way repeated measures ANOVA indicated that
there were no significant main effects of instruction (F[1, 14] = .36, p = .558, η2p = .025) or
administration (F[1, 14] = 4.23, p = .059, η2p = .232) on pain threshold. There was no significant
interaction between instruction and administration (F[1, 14] = .06, p = .807, η2p = .004) on pain
threshold.
Tolerance
As seen in Table 4 results from the two-way repeated measures ANOVA indicated that
there were no significant main effects of instruction (F[1, 14] = .68, p = .425, η2p = .046) or
administration (F[1, 14] = .55, p = .469, η2p = .038) on pain tolerance. There was no significant
interaction between instruction and administration (F[1, 14] = .16, p = .696, η2p = .011) on pain
tolerance.
Intensity
As seen in Table 4, results from the two-way repeated measures ANOVA indicated that
there were no main effects of instruction (F[1, 14] = 3.65, p = .077, η2p = .207) or administration
(F[1, 14] = .22, p = .650, η2p = .015) on pain intensity. There was no significant interaction
between instruction and administration (F[1, 14] = 3.10, p = .100, η2p = .181) on pain intensity.
Unpleasantness
As seen in Table 4 results from the two-way repeated measures ANOVA indicated that
there were no main effects of instruction (F[1, 14] = 2.50, p = .136, η2p = .152) or administration
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(F[1, 14] = 1.66, p = .219, η2p = .106) on pain unpleasantness. As seen in Figure 5, results
revealed a significant, large effect size interaction between instruction and administration (F[1,
14] = 8.45, p = .011, η2p = .376) on pain unpleasantness.
In follow-up comparisons, paired-samples t-tests revealed significantly greater pain
unpleasantness reductions in the expectancy (t[14] = 3.26, p = .006, d = .860), drug (t[14] =
3.17, p = .007, d = .820), and expectancy + drug conditions (t[14] = 2.36, p = .033, d = .616)
when compared to the control condition. These simple main effects were medium to large in size
(Cohen, 1988). As illustrated in Figure 4, the largest reductions in pain unpleasantness occurred
in the placebo (told CBD – given coconut oil) condition.
Conditioned Pain Modulation (CPM)
Figure 6 presents the mean CPM change scores (% decrease) in each condition. As seen
in Table 4, results from the two-way repeated measures ANOVA indicated that there were no
main effects of instruction (F[1, 14] = .09, p = .774, η2p = .006) or administration (F[1, 14] = .45,
p = .513, η2p = .031) on CPM. As seen in Figure 6, results revealed a significant, large effect size
interaction between instruction and administration (F[1, 14] = 7.07, p = .019, η2p = .336) on
CPM.
In follow-up comparisons, paired-samples t-tests revealed significantly greater CPM
responses (i.e., more pain inhibition) in the expectancy (t[14] = -2.75, p = .016, d = -.76), and
drug (t[14] = -3.20, p = .006, d = -0.84) when compared to expectancy + drug condition. These
effects were medium to large in size (Cohen, 1988). As illustrated in Figure 7, the greatest prepost increases in the CPM response occurred in the expectancy (told CBD – given coconut oil)
condition.
Offset analgesia (OA)
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Figure 8 presents the CoVAS time-series ratings for OA in each condition. As seen in
Table 4, results from the two-way repeated measures ANOVA revealed a significant, large effect
size main effect of instruction (F[1, 14] = 7.58, p = .016, η2p = .351) on OA. Significant
increases in offset analgesia were observed when participants were told they received CBD,
regardless of drug administration. There was no main effect of administration (F[1, 14] = .47, p
= .506, η2p = .032) and no interaction (F[1, 14] = .13, p = .724, η2p = .009).
Discussion
Using a balanced placebo design, we experimentally tested the effects of cannabidiol
(CBD) and analgesic expectancies on human pain reactivity (i.e., pain threshold, tolerance,
intensity, unpleasantness, conditioned pain modulation, offset analgesia) by manipulating both
drug administration (given coconut oil or given CBD) and instructions (told coconut oil or told
CBD) among healthy humans. We hypothesized finding significant analgesic effects of the
instructional set (expectancy) manipulation, but null effects for drug administration and
interactions. We did not find significant main or interaction effects for pain threshold, tolerance,
or intensity, indicating that our hypotheses were not supported for these outcomes. As
hypothesized, there was a significant main effect of instructions on OA, such that the OA
response was significantly larger (e.g., greater pain inhibition) when participants were told that
they received CBD, regardless of drug content. Our hypotheses were only partially supported for
the pain unpleasantness and CPM results, as the analgesic responses we observed for these
outcomes were driven by both expectancy and drug effects. Overall, our results indicated that
separate pain outcomes can be differentially affected by CBD and/or expectancies for receiving
CBD. These findings suggest that the analgesic profile for CBD is complex and multifaceted.
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The effects of CBD and expectancies for receiving CBD on pain unpleasantness were the
most robust among the static QST outcomes. Our results were consistent with previous metaanalytic findings that cannabinoid administration primarily decreases the unpleasantness
(affective dimension) but not intensity (sensory dimension) of experimental pain (De Vita et al.,
2018). Until now, cannabinoid analgesia trials have been unable to determine whether decreases
in unpleasantness were attributable to intoxication (e.g., “feeling high”), expectancies,
pharmacological action, or some interaction among them. This is primarily because blinding
procedures in placebo-controlled trials are confounded by psychoactive side-effects. Our study
successfully overcame these methodological limitations by testing a non-psychoactive
cannabinoid (CBD) using a balanced placebo design. Specifically, we found that cannabinoidinduced reductions in pain unpleasantness were caused by both psychological expectancies for
receiving a CBD analgesic and pharmacological administration of CBD. Notably, these findings
occurred in the absence of intoxicating side-effects, which remain a salient concern among those
considering cannabinoid-based medicines for pain (Hill et al., 2017; Izzo et al., 2009; Lötsch et
al., 2017). Although pain unpleasantness is related to functional status outcomes, such as painrelated interference (Boggero & Carlson, 2015), improvements in functionality may be offset by
cannabinoid intoxication. Psychoactive cannabinoids may not suffice when treatment aims to
relieve pain without producing intoxication. However, our results suggest that CBD may relieve
pain unpleasantness while mitigating these concerns. Given its low abuse liability and good
safety profile (Babalonis et al., 2017), CBD may indeed be a potential therapeutic alternative to
traditional cannabinoid-based analgesics.
Mechanistic Considerations
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Mechanistic insights can be drawn from the QST results obtained in this study. Our
finding that expectancies for receiving CBD and administration of CBD reduced pain
unpleasantness is consistent with pre-clinical studies on cannabinoid signaling in the nociceptive
system (Lötsch et al., 2017). Rodent models suggest that cannabinoids reduce the stress response
by acting on CB1 receptors, which may alter affective responses to pain and the ability to cope
with pain-induced stress (Busquets-Garcia et al., 2016; Rácz et al., 2015). Cannabinoids have
been shown to activate peripheral CB2 receptors as well, resulting in the release of endogenous
opioids that reduce nociception (Ibrahim et al., 2005; Ibrahim et al., 2006). Centrally, brain
circuits that are associated with pain modulation are densely populated with CB2 receptors
(Beltramo et al., 2006; Elmes et al., 2004; Shang & Tang, 2017). Notably, our results suggest
that expectancies for receiving CBD and administration of CBD enhance central nervous system
processes that inhibit pain (i.e., descending inhibition). Conditioned pain modulation (CPM) and
offset analgesia (OA) evaluate endogenous systems that promote descending pain inhibition via
spatial and temporal processing, respectively (Grill & Coghill, 2002; Pud et al., 2009). We
observed an amplified CPM response in both the drug and expectancy conditions, indicating that
CBD and expectancies for receiving CBD can independently enhance endogenous inhibition
mediated by spatial pain processing. OA was exclusively enhanced by telling participants they
received CBD, regardless of what was actually administered. Thus, expectancies for receiving
CBD enhanced endogenous pain inhibition mediated by temporal processing. Importantly,
expectancies played a large role in amplifying both CPM and OA. Numerous chronic pain
conditions (e.g., fibromyalgia, chronic tension headache, complex regional pain syndrome) are
characterized by deficiencies in endogenous pain inhibition (King et al., 2009; Lautenbacher &
Rollman, 1997; Olesen et al., 2010; Seifert et al., 2009). Our results suggest that CBD may
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improve such deficiencies, particularly when analgesic expectancies are leveraged to optimize
central effects. Our findings are consistent with those from neuroimaging studies that implicate
top-down inhibiting mechanisms in expectancy-induced analgesia (Eippert et al., 2009).
Expectancy-induced analgesia reduces nociceptive processing in the dorsal spinal cord,
implicating processing between cortical regions and descending pain inhibitory systems (Eippert
et al., 2009; Medoff & Colloca, 2015). Our results support this observation, as expectancies for
receiving a CBD analgesic enhanced spatial and temporal measures of central descending
inhibition. Given that CBD pharmacodynamics are still not completely understood, additional
research is needed to explicate specific mechanisms underlying CBD analgesia.
Clinical Implications
Expectancy-Induced Analgesia
The finding that expectancies play a large role in CBD analgesia has several clinical
implications. Indeed, there is an emerging clinical consensus that expectancy-induced analgesia
can, and should, be leveraged to enhance pain interventions (Bingel, 2013; Castelnuovo et al.,
2018; Colloca, 2019; Evers et al., 2018; Klinger et al., 2014; Klinger et al., 2018; Peerdeman,
Van Laarhoven, Peters, et al., 2016; Sanders et al., 2020). Integrative models of pain and
expectancies describe several processes (e.g., instructional learning, conditioning, social
observations) that can influence placebo analgesia (Bajcar & Bąbel, 2018; Colloca, 2019;
Peerdeman, Van Laarhoven, Peters, et al., 2016). Brief psychological interventions that employ
these processes may promote analgesic expectancies and optimize pain treatments. Verbal
instructions about analgesic treatment outcomes are particularly effective in reducing clinical
pain (Peerdeman, van Laarhoven, Keij, et al., 2016). Adequate analgesic expectancies could be
consolidated by verbally reinforcing the cognitive and emotional impact of positive treatment
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results. Inadequate expectancies (i.e., overly-negative or overly-positive cognitions) may be
altered via re-attribution training to be more realistic and clinically useful (Bingel, 2013).
Verbally emphasizing the positive and realistic effects of CBD on pain, without overemphasizing
negative side-effects, may optimize analgesic responses. This should include information about
known mechanisms (e.g., psychological and pharmacological effects), and how placebo
analgesia can be utilized to enhance self-management skills (Klinger et al., 2014). Conditioning
processes may involve reinforcing successful features of treatment experiences while altering
less desirable aspects (Peerdeman, Van Laarhoven, Peters, et al., 2016). For instance, patients
often express concern about intoxicating side-effects when using cannabis for pain relief (Lötsch
et al., 2017). Switching from cannabis to CBD might maintain a patient’s positive expectancies
about cannabinoid analgesia while reducing negative expectancies for adverse side-effects.
Social learning may be facilitated by interacting with others who hold positive expectancies, or
by exposure to media (e.g., online video) that promotes analgesic expectancies (Bajcar & Bąbel,
2018; Hunter et al., 2014; Peerdeman, Van Laarhoven, Peters, et al., 2016). Although
expectancy interventions are promising for optimizing analgesic treatments, several
considerations are worth noting. Deception should not be considered a necessary treatment
component (Evers et al., 2018), as expectancy-induced analgesia can occur even when
individuals are aware that they are using placebo (Carvalho et al., 2016; Locher et al., 2017).
Instead, explaining expectancy effects and their clinical use has been encouraged (Klinger et al.,
2014; Klinger et al., 2018). Overstatements about CBD analgesia should be avoided, as this can
lead to negative treatment outcomes when exaggerated expectancies are not fulfilled (Klinger et
al., 2014). Importantly, expectancy interventions may complement, but not replace, first-line
evidence based pain treatments (Forsberg et al., 2017; Sanders et al., 2020). Nonetheless, a
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systematic approach to expectancy assessment and intervention may help capitalize on the
clinical utility of CBD analgesia.
Strengths, Limitations, and Future Directions
The current study has several notable strengths. It is the first balanced placebo design
experiment to examine both drug and expectancy effects in cannabinoid analgesia. This study is
also the first to test the effects of a non-psychoactive cannabinoid, cannabidiol (CBD), on human
pain reactivity. This is an important methodological departure from extant studies that have
administered psychoactive cannabinoids (e.g., THC) exclusively. Our novel approach enhanced
the feasibility of experimental manipulations while overcoming blinding failures that confound
many placebo-controlled cannabinoid trials. Additionally, our method of assessing analgesic
responses was highly advanced, as it involved the use of cutting-edge quantitative sensory testing
technology that yielded psychophysiological insights.
Despite its strengths, several limitations should be considered in interpreting this study’s
findings. Our study employed experimental pain measures, which approximate features of
clinical pain (McMahon et al., 2013). To produce evidence supporting the generalizability of the
current findings, pain reactivity research must be conducted in clinical samples.
These concerns notwithstanding, cumulative results from research on other drugs (e.g., opioids)
have consistently demonstrated that analgesia can be evaluated using laboratory pain
assessments (McMahon et al., 2013). These findings support assertions that complex pain
processes may be best evaluated using experimental pain methods, such as those employed in the
current study, to yield insights into multiple aspects of the pain experience. By determining
which dimensions of pain are affected by CBD and expectancies, our study has yielded a profile
that characterizes CBD analgesia. Given that the pathology underlying chronic pain varies
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widely between conditions (Edwards et al., 2016), CBD analgesia in chronic pain populations
may highly variable. The analgesic effects we observed in this study may be more generalizable
to chronic pain conditions characterized by affective pain impairments (e.g., increased pain
unpleasantness) and deficits in descending pain inhibition (e.g., offset analgesia, conditioned
pain modulation). CBD may be less effective for pain conditions characterized by impairments in
pain threshold, tolerance, and intensity. Capitalizing on the effectiveness of CBD analgesia
would involve identifying compatibility between the analgesic profile of CBD and the
pathological profile of particular chronic pain conditions. This type of mechanism-based pain
management is an emerging field, and more empirical work is needed to optimize this approach
(Cruz-Almeida & Fillingim, 2014). The age range in our study was limited to young adults
between 18 and 27 years old. The effects observed in this study may vary as a function of age for
various reasons. Different age groups may hold distinct expectancies for cannabinoids due to
their lifetime experiences. For cannabinoid drugs, especially CBD, there has been a dramatic
shift in societal attitudes/beliefs, public policy, and empirical knowledge within recent years.
Motives for CBD use may also differ between age groups. Whereas younger adults may use
CBD recreationally or as part of a health/lifestyle regimen, older adults may be motivated to use
CBD to treat conditions that commonly co-occur with aging, such as chronic pain. More research
is needed to characterize attitudes, beliefs, expectancies, and motives regarding CBD use in
different age groups. Experimental work that tests the analgesic effects of CBD and analgesic
expectancies in different age groups is also warranted. Our study was unable to account for
previous experience with using cannabis and CBD, which is an important factor to consider in
future research. Expectancies can be largely shaped by experiences, so positive or negative
experiences with cannabinoid drugs may influence placebo or nocebo effects, respectively.
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Whereas we administered pure CBD in our study, the contents within widely-available nonprescription CBD products that most consumers use are highly variable. People with previous
experience using CBD products containing other cannabinoids (i.e., THC) may have different
expectancies for how CBD affects them personally. Examining how previous experience with
using various CBD preparations influences analgesic effects would be an important direction for
future research. Prolonged chronic use of cannabinoid drugs may also lead to increased tolerance
of their effects. Longitudinal research is needed to determine whether heavier/longer cannabinoid
use histories are associated with analgesic tolerance and dysregulated pain processing. Our study
was limited to testing acute analgesic effects. Future studies would benefit from testing painreactivity over longer periods to better characterize the analgesic profile of CBD. Furthermore,
CBD in the current study was limited to a single 50mg dose administered sublingually. Future
research should examine the CBD analgesia using varying doses, preparations (e.g., fullspectrum vs. isolate), and administration routes. Lastly, our study was limited by a modest
sample size. CBD drug effects may be smaller and less stable than those found for expectancies.
Larger sample sizes in future research would likely yield more stable effect size estimates and
would increase power to detect moderating effects using between-subjects factors (e.g., gender).
Future work may also benefit from exploring the influence of relevant psychological
variables on the effects observed in this study. Different measures of pain-related affect,
cognition, attitudes, and beliefs may yield insights into how cannabinoids and expectancies affect
pain. For example, CBD and analgesic expectancies may reduce pain catastrophizing, a construct
characterized by distressing emotional and cognitive responses to experienced or anticipated pain
(Rosenstiel & Keefe, 1983; Sullivan et al., 1995). Pain catastrophizing can influence the pain
experience, and has been suggested as a useful model for studying placebo analgesia (Darnall &
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Colloca, 2018). Indeed, CBD- and/or expectancy-induced reductions in pain catastrophizing may
mediate analgesic responses, especially for the affective dimension of pain (e.g., unpleasantness).
Research should also continually investigate how social influences (e.g., public advocacy,
political agendas, media representations) are reshaping health-related attitudes and beliefs about
the risks and benefits of cannabinoid-drugs. It would also be important to study how these factors
contribute to expectancies about the effectiveness of CBD for pain relief. Given the effects
observed in this study, cannabinoid analgesia may very likely be susceptible to influence from a
variety of psychological factors.
Other types of analgesic-related expectancies should also be examined in future research.
The current study tested the analgesic effects of expectancies for whether an analgesic substance
(i.e., CBD) was received, which differ from expectancies about whether CBD relieves pain. The
strength of one’s expectancies for pain relief following cannabinoid administration may
moderate the size of analgesic responses. After receiving verbal information that CBD has been
administered, people who expect more pain relief from cannabinoids may experience greater
analgesia than those who expect smaller or no effects. Individuals with negative expectancies
may even experience nocebo effects (e.g., hyperalgesia). Understanding how expectancies for
cannabinoid analgesia affect pain reactivity could optimize pain treatments that aim to strengthen
placebo effects while minimizing nocebo effects. In this regard, future work that validates
measures of expectancies for cannabinoid effects on multiple pain-related dimensions (e.g.,
affective, sensory, attentional; see Appendix K) is warranted. Future research should test whether
expectancies for cannabinoid analgesia moderate the effects identified in this study.
Additionally, future studies should examine whether increasing expectations that CBD relieves
pain further enhances the analgesic drug and expectancy effects observed in our study.
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Conclusions
The findings from this study have helped characterize how CBD and expectancies for
receiving CBD affect different dimensions of pain reactivity. We determined that expectancies
played a large role in CBD analgesia. Consistent with previous findings (De Vita et al., 2018),
our results showed CBD and expectancies for receiving CBD primarily reduced pain
unpleasantness. We also found that central measures of endogenous pain inhibition (i.e., CPM,
OA) were differentially affected by CBD and expectancies. Whereas CPM was amplified in both
the drug and expectancy conditions, OA was primarily enhanced by expectancies for receiving
CBD. Given the results of the current study, future investigations of the psychological and
pharmacological mechanisms underlying CBD analgesia are warranted.
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Table 1.
Sociodemographic and Substance Use Characteristics
Participant Characteristics
Sample N (%)
Total Sample Size
15
Gender
Female
10 (66.7)
Income
<30K
6 (40.0)
30-50K
2 (13.3)
>50K
7 (46.7)
Education
High school graduate
2 (13.3)
Some college
9 (60.0)
Four-year college degree
2 (13.3)
School beyond 4-year degree
2 (13.3)
Marital Status
Single
15 (100)
Ethnicity
Hispanic/Latino
4 (26.7)
Not Hispanic/Latino
11 (73.3)
Race
Caucasian
8 (53.3)
Black/African American
2 (13.3)
Asian
4 (26.7)
Native Hawaiian or Other Pacific
1 (6.7)
Islander
Have you ever used Cannabidiol/CBD?
Yes
10 (66.7)
No
5 (33.3)
Do you personally know anyone who has used
Cannabidiol/CBD?
Yes
12 (80.0)
No
3 (20.0)
M (SD)
Age
20.73 (2.60)
AUDIT Total1
4.20 (2.54)
CUDIT-R Total2
3.13 (2.61)
PACE Total3
69.93 (14.06)
30-Day TLFB4
% Drinking Days
17.33 (17.19)
% Cannabis-Use Days
10.22 (24.67)
MSHQ5
Frequency
2.62 (1.85)
Quantity
2.38 (1.50)
Years of Cannabis Use
3.10 (1.72)
Age of Onset
16.46 (1.66)
Note. 1Alcohol Use Disorders Identification Test; 2Cannabis Use
Disorders Identification Test – Revised; 3Pain and Cannabinoid
Expectancies; 4Timeline-Followback; 5Marijuana Smoking History
Questionnaire.
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Table 2
Bivariate Pearson Correlations between QST Change Scores and Age, Gender, CBD/Cannabis Ever Use, Expectancies for Cannabinoid Analgesia, and Counterbalanced Order
Cannabis
Ever Use

Expectancies for
Cannabinoid
Analgesia
Sum Score

Counterbalanced
Order

Age

Gender

CBD
Ever Use

Threshold - (Control) Told Inactive/Given Inactive

-.098

-.208

.338

.305

.347

.173

Threshold - (Expectancy+Drug) Told Active/Given Active

-.184

-.166

-.045

-.049

.074

-.425

Threshold - (Drug) Told Inactive/Given Active

.231

-.187

.025

-.397

.288

-.060

Threshold - (Expectancy) Told Active/Given Inactive

-.266

-.475

-.004

.139

.408

.357

Tolerance - (Control) Told Inactive/Given Inactive

.432

-.245

-.281

.152

-.104

-.257

Tolerance - (Expectancy+Drug) Told Active/Given Active

.175

.285

-.042

-.442

-.100

-.430

Tolerance - (Drug) Told Inactive/Given Active

.461

-.319

.075

-.245

-.039

.209

*

-.494

Tolerance - (Expectancy) Told Active/Given Inactive

-.222

-.240

.474

-.119

.561

Intensity - (Control) Told Inactive/Given Inactive

-.593*

-.169

-.057

.251

-.108

.156

Intensity - (Expectancy+Drug) Told Active/Given Active

-.097

-.097

-.162

.005

-.025

.345

Intensity - (Drug) Told Inactive/Given Active

-.075

.392

.429

.203

-.186

-.009

Intensity - (Expectancy) Told Active/Given Inactive

.284

.127

-.355

.259

-.083

-.243

Unpleasantness - (Control) Told Inactive/Given Inactive

-.437

.158

.114

.182

-.007

.308

Unpleasantness - (Expectancy+Drug) Told Active/Given Active

-.048

.166

.174

.204

Unpleasantness - (Drug) Told Inactive/Given Active

.197

.540

*

.471

Unpleasantness - (Expectancy) Told Active/Given Inactive

.228

.312

OA - (Control) Told Inactive/Given Inactive

.045

.510

OA - (Expectancy+Drug) Told Active/Given Active

-.033

OA - (Drug) Told Inactive/Given Active

.327

.225

.416

*

-.078

-.037

-.016

.000

.121

-.252

.470

-.503

-.028

.107

.303

.066

-.112

-.344

-.244

-.231

-.342

.179

-.366

.347

-.564

OA - (Expectancy) Told Active/Given Inactive

-.047

.098

.256

.060

.175

.234

CPM - (Control) Told Inactive/Given Inactive

-.305

.358

.053

.050

-.305

.482

CPM - (Expectancy+Drug) Told Active/Given Active

-.186

-.119

-.090

.196

-.148

-.231

CPM - (Drug) Told Inactive/Given Active

-.462

-.231

.162

.405

-.356

.143

CPM - (Expectancy) Told Active/Given Inactive
Note. N = 15.
*p < .05, ** p < .01, *** p < .001

-.382

-.168

-.401

.018

-.701

**

.350
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Table 3
Two-Way Repeated Measures ANOVA Results for Cannabis-Related Side Effects
Outcome
MS
F(1, 14)
p
η2p
Drowsiness
Instruction
117.60
.71
.413
.048
Administration
117.60
2.03
.176
.127
Interaction
38.40
.38
.548
.026
Euphoria
Instruction
135.00
.82
.379
.056
Administration
41.67
1.03
.327
.069
Interaction
86.40
1.29
.276
.084
Sedation
Instruction
10.42
.07
.801
.005
Administration
183.75
1.46
.247
.095
Interaction
62.02
.40
.536
.028
Nausea
Instruction
1.07
.24
.630
.017
Administration
1.07
.22
.650
.015
Interaction
.60
.12
.734
.009
Dry Mouth
Instruction
209.07
3.03
.104
.178
Administration
81.67
.51
.489
.035
Interaction
.00
.00
1.00
.000
Vertigo
Instruction
8.07
.67
.429
.045
Administration
.60
.06
.815
.004
Interaction
1.67
.13
.727
.009
2
Note. N = 15. MS = Mean Square; η p = Partial Eta Squared (effect size).
*p < .05, ** p < .01, *** p < .001
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Table 4
Two-Way Repeated Measures ANOVA Results for QST Outcomes
Outcome
MS
F(1, 14)
p
Pain Threshold
Instruction
.52
.36
.558
Administration
18.29
4.23
.059
Interaction
.16
.06
.807
Pain Tolerance
Instruction
.34
.68
.425
Administration
.16
.55
.469
Interaction
.04
.16
.696
Pain Intensity
Instruction
256.27
3.65
.077
Administration
8.56
.22
.650
Interaction
125.19
3.10
.100
Pain Unpleasantness
Instruction
180.27
2.50
.136
Administration
84.81
1.66
.219
Interaction
548.03
8.45
.011*
Conditioned Pain Modulation
Instruction
32.12
.09
.774
Administration
326.28
.45
.513
Interaction
1942.75
7.07
.019*
Offset Analgesia
Instruction
4072.76
7.58
.016*
Administration
304.91
.47
.506
Interaction
110.35
.13
.724
2
Note. N = 15. MS = Mean Square; η p = Partial Eta Squared (effect size).
*p < .05, ** p < .01, *** p < .001

η2p
.025
.232
.004
.046
.038
.011
.207
.015
.181
.152
.106
.376
.006
.031
.336
.351
.032
.009
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Table 5.
Mean (Standard Deviation) Pre, Post, and Change Score Values for QST Variables within Conditions
Control
Expectancy
Drug
Expectancy + Drug
(told inactive – given inactive)
(told active – given inactive)
(told inactive – given active)
(told active – given active)
Pre
Post
Pre
Post
Pre
Post
Outcome
Pre
Post
Δ
Δ
Δ
Δ
Threshold (°C)
42.88
42.23
-0.65
42.53
41.97
-0.56
41.56
41.92
0.35
42.47
43.11
0.64
(3.47)
(3.81)
(2.24)
(3.16)
(3.83)
(1.63)
(4.01)
(4.31)
(1.89)
(3.61)
(3.21)
(1.24)
Tolerance (°C)
46.74
46.46
-0.28
46.61
46.43
-0.18
46.64
46.42
-0.23
46.90
46.87
-0.02
(1.21)
(1.06)
(0.57)
(0.92)
(0.78)
(0.40)
(1.49)
(2.13)
(0.95)
(1.04)
(1.02)
(0.51)
Intensity (VAS)
32.93
34.91
1.98
38.49
33.44
-5.04
39.02
37.36
-1.67
34.78
31.87
-2.91
(17.20)
(18.91)
(6.25)
(20.61)
(17.00)
(7.92)
(23.83)
(22.65)
(9.33)
(18.84)
(15.61)
(6.22)
Unpleasantness (VAS)
27.53
30.22
2.69
35.00
28.18
-6.82
35.58
29.84
-5.73
29.18
26.02
-3.16
(15.46)
(18.37)
(7.00)
(20.02)
(15.75)
(10.06)
(24.94)
(20.54)
(7.87)
(18.52)
(15.01)
(8.62)
CPM1
71.64
78.71
7.07
73.75
93.66
19.91
73.93
87.71
13.79
84.70
88.57
3.87
(29.49)
(30.01)
(40.52)
(24.23)
(17.11)
(23.89)
(24.58)
(23.69)
(16.48)
(19.53)
(17.31)
(13.78)
OA2
85.03
86.35
1.33
77.58
92.67
15.09
88.95
83.06
-5.90
79.01
92.30
13.30
(25.86)
(20.67)
(26.74)
(28.64)
(17.02)
(32.82)
(16.72)
(29.35)
(28.67)
(27.71)
(13.25)
(18.35)
Note. N = 15. Inactive = coconut oil; Active = CBD oil; Δ = Change Score (post minus pre); 1Condition Pain Modulation CoVAS % Decrease (peak to nadir); 2Offset Analgesia CoVAS % Decrease (peak to nadir).
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Figure 1
Two by Two Balanced Placebo Design

Note. Active = CBD oil; Inactive = coconut oil.
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Figure 2
Overview of Experimental Session Procedures

Note. Order of manipulations conditions was counterbalanced in a randomized fashion. Active =
CBD oil; Inactive = coconut oil.
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Figure 3
CONSORT Participant Flow Diagram

Note. CONSORT diagram illustrating participant enrollment, allocation, follow-up, and analysis.
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Figure 4
Mean Change Scores for Static QST Variables

Note. Mean change scores (post minus pre) for static QST variables in each condition. Error bars
represent standard error. For pain unpleasantness, simple main effects comparing control to all
other conditions are displayed.
*p < .05
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Figure 5
Pain Unpleasantness Interaction Plot

Figure 5. Interaction effect of instruction set and drug administration on pain unpleasantness.
Active = CBD oil; Inactive = coconut oil.
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Figure 6
Conditioned Pain Modulation CoVAS Data

Note. Composite CoVAS data (pre- and post-manipulation) from all 15 participants in each
condition for conditioned pain modulation (CPM).
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Figure 7
Conditioned Pain Modulation Interaction Plot

Note. Interaction effect of instruction set and drug administration on CPM. Active = CBD oil;
Inactive = coconut oil.
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Figure 8
Offset Analgesia CoVAS Data

Figure 8. Composite CoVAS data (pre- and post-manipulation) from all 15 participants in each
condition for offset analgesia (OA).
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Appendix A: Example CoVAS Data
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Appendix B: Screener Items
Screener Items

1
2
3
4
5
6
8
9
10
11
12
13
14
15
16
17

Notes:

Eligibility Questions

Eligible

Ineligible

What is your date of birth? DOB: ___/___/___
How old are you?
Are you currently experiencing any pain? (If yes, ask
the individual about type, location duration, and
severity)
Are you currently taking any pain medication?
Are you currently, or have you ever been diagnosed
with a chronic medical condition (e.g., diabetes, heart
disease, cancer)?
Have you ever been diagnosed with or think you have
had a mental health disorder?
Have you ever been diagnosed with or think you have
had a substance use disorder?
Are you currently prescribed any medication for any
physical or mental health condition? (except birth
control, vitamins, etc.)
Are you a current or former tobacco user?
Do you use other products containing nicotine,
including pipe tobacco, e-cigarettes, JUULs, vaping
devices, or chewing tobacco?
(For females) Are you pregnant, breast feeding, or
planning to become pregnant in the next 4-6 months?
Do you speak and read English well?
Do you have any coconut allergies?
CUDIT-R
AUDIT
CBM-Q item 3 response (circle one)
Is participant eligible?

(≥18 & ≤ 30 yrs)
Age:____

(<18 & >30 yrs)
Age:____

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

Yes
No
Total score <8:
Total score <8:
Yes or Maybe
Yes

No
Yes
Total score >8:
Total score >8:
No
No
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Appendix C: Condition Information
Counterbalanced order randomization:
A = Told Inactive/Given Inactive (Coconut Oil with Coconut Flavor)
B = Told Active/Given Active (CBD with Mary Jane Flavor)
C = Told Inactive /Given Active (CBD with Coconut Flavor)
D = Told Active/Given Inactive (Coconut Oil with Mary Jane Flavor)

Participant ID
001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016

Order Number
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2

Session 1
C
D
A
B
C
D
A
B
C
D
A
B
C
D
A
B

Session 2
D
A
B
C
D
A
B
C
D
A
B
C
D
A
B
C

Session 3
A
B
C
D
A
B
C
D
A
B
C
D
A
B
C
D

Session 4
B
C
D
A
B
C
D
A
B
C
D
A
B
C
D
A

Instructions for each condition:
A: “In today’s session, you will not be receiving the pain-reliever, cannabidiol. Instead, you will be given control dose of
coconut oil, which does not have any effects on anything, including pain.”
B: “In today’s session, you will be receiving a concentrated dose of cannabidiol, or CBD. This experimental CBD produces
strong pain-relieving effects without making you high, or producing any other negative mind altering effects.”
C: “In today’s session, you will not be receiving the pain-reliever, cannabidiol. Instead, you will be given control dose of
coconut oil, which does not have any effects on anything, including pain.”
D: “In today’s session, you will be receiving a concentrated dose of cannabidiol, or CBD. This experimental CBD produces
strong pain-relieving effects without making you high, or producing any other negative mind altering effects.”
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Appendix D: Alcohol Use Disorders Identification Test (AUDIT)
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Appendix E: The Cannabis Use Disorders Identification Test – Revised (CUDIT-R)

56
Appendix F: Cannabis-Based Medicines Questionnaire (CBM-Q)

Please answer to the best of your knowledge.
Cannabis-based medicines and medical marijuana are helpful for
which of the following conditions?
No

Cancer
Glaucoma
Pain
Nausea
Epilepsy
Anxiety
Depression
Inflammation
Diabetes
Dementia

Maybe

Yes
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Appendix G: Demographic Questionnaire
The following questions are about yourself and your life situation.
Gender
Male
Female
Non-Binary/Third Gender
Prefer to self-describe __________________

What is your age? ___________________________
Date of Birth (mm/dd/yyyy) ____________________
What is your marital status?
Single
Married
Separated
Divorced
Widowed

With which racial category do you most identify yourself?
American Indian/Alaska Native
Asian
Native Hawaiian or Other Pacific Islander
Black or African American
White

Are you Hispanic/Latino?
Yes
No

What is the highest grade level you have completed?
Did not graduate high school
High school graduate
Some college
Technical school/Associates degree
4-year college degree
Some school beyond 4-year college degree
Professional degree (e.g. MD, JD, PhD)

What year are you in college?
Pre-Freshman
Freshman
Sophomore
Junior
Senior
5th year or above

What is your current GPA: _______
What is your total household income?
Under $10,000
$10,000-$19,999
$20,000-$29,999
$30,000-$39,999
$40,000-$49,999
$50,000-$59,999
$60,000-$69,999
$70,000-$79,999
$80,000-$89,999
Over $90,000

For women: What was the start date of your last period (the day you actually started bleeding)? Enter in (mm/dd/yyyy)
________________________________________________________________
For women: On average, how many days does your menstrual cycle last? (Count the day you actually start bleeding as
Day 1 and count the average number of days up until the day before your next period begins)
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Appendix H: Timeline Followback
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Appendix I: The Marijuana History and Smoking Questionnaire (MHSQ)

Open ended questions about CBD:
Have you ever used cannabidiol/CBD?
Please describe: _____________________________
Do you personally know anyone who has used
Cannabidiol/CBD? Please
describe:____________________________
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Appendix J: Perceived Drug Side Effects (Visual Analog Scales)
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Appendix K: Expectancies for Cannabinoid Analgesia
This questionnaire contains statements that about cannabis and pain. Please rate how you would expect cannabis to
affect the experience of pain. Please try your best to answer these questions as honestly as possible.

Please rate the degree to which you expect the
following statements to be true:

1.

Cannabis makes pain feel less unpleasant.

2.

Cannabis makes people not care about pain.

3.

Cannabis distracts people from pain.

4.

Cannabis reduces the intensity of pain.

5.

Cannabis improves the ability to tolerate pain.

6.

Cannabis makes people forget about the pain.

7.

Cannabis makes pain more manageable.

8. Cannabis alleviates the negative emotions
related to pain.
9.

Cannabis helps people cope with pain.

10. Cannabis takes your mind off of the pain.
11. Cannabis has pain-relieving properties.
12. Cannabis improves the mood of people in pain.
13. Cannabis makes pain more bearable.
14. Cannabis allows people to not focus on the pain.
15. Cannabis numbs the pain out.
16. Cannabis is an effective painkiller.
17. Cannabis makes people in pain feel happier.
18. Cannabis makes pain feel less bothersome.
19. Cannabis relieves the stress of having pain.
20. Cannabis dampens physical pain sensations.

Definitely
Not

Probably
Not

Probably

Very
Probably

Definitely

0

1

2

3

4
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Appendix L: Instructional Set Manipulation Checks
At the end of each session:
Which dose did you receive in today’s session? (select one)
Coconut Oil
Cannabidiol (CBD)

At the end of the experiment:
At any point during this experiment, did you suspect that the researchers were deceiving you?
Yes
No

If so, please explain:
_________________________________________________________________________________________________
_________________________________________________________________________________________________
_________________________________________________________________________________________________
_________________________________________________________________________________________________
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Appendix M: CBD Isolate Product Information
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Appendix N: Examples of Guides for CBD Use from Manufacturers
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